<DOC>
	<DOCNO>NCT01537900</DOCNO>
	<brief_summary>The goal study compare hepatic pharmacokinetics ( PK ) derive liver tissue plasma PK administration grazoprevir ( MK-5172 ) participants chronic hepatitis C virus ( HCV ) infection . Participants randomize one four different liver ultrasound-guided Fine Needle Aspirate ( FNA ) schedule ( 4- , 8- , 24- , 72-hours Day 7 dose ) .</brief_summary>
	<brief_title>A Multiple Dose Study Grazoprevir ( MK-5172 ) Hepatitis C-Infected Participants ( MK-5172-010 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Inclusion criterion : Body Mass Index ( BMI ) ≥18.5 kg/m² ≤36.0 kg/m² chronic compensate , genotype 1 HCV infection cirrhosis liver confirm FibroSure®/Fibro Test® and/or local country procedure ( e.g . transient elastography/Fibroscan ) require anticoagulant , nonsteroidal antiinflammatory agent , aspirin least fourteen ( 14 ) day precede initial liver biopsy continue throughout entire study female participant reproductive potential , willing use 2 medically acceptable form contraception 2 week prior start treatment 2 week last study treatment male participant partner ( ) reproductive potential , willing use 2 medically acceptable form contraception first dose 90 day last dose Exclusion criterion : history stroke , chronic seizure , major neurological disorder receive previous treatment directacting antiviral ( DAA ) evidence high grade bridge fibrosis prior liver biopsy within 3 year study entry evidence history chronic hepatitis cause HCV infection include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis clinical laboratory evidence cirrhosis advance liver disease decompensated liver disease indicate history ascites , hepatic encephalopathy , bleed esophageal varix diagnose , suspect , hepatocellular carcinoma ( HCC ) clinically significant abnormality electrocardiogram ( ECG ) coinfected human immunodeficiency virus ( HIV ) positive Hepatitis B surface antigen ( HBsAg ) evidence active Hepatitis B infection history gastric bypass surgery , bowel resection disorder may interfere absorption history clinically significant uncontrolled endocrine , gastrointestinal , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases clinically significant neoplastic disease use alcohol excess , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 354 mL ] , wine [ 118 mL ] , distilled spirit [ 29.5 mL ] ) per day current regular user ( include use illicit drug ) history drug ( include alcohol ) abuse within last 3 month undergone surgery , donation 1 unit blood ( approximately 500 mL ) participation another investigational study within period 4 week prior screen visit history multiple and/or severe allergy , anaphylactic reaction intolerability prescription nonprescription drug food pregnant lactating expect donate egg sperm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>